期刊文献+

SDF-1、CXCR4及ERK1/2在病理性瘢痕中的表达及临床意义 被引量:3

Expression of stromal cell-derived factor 1,CXCR4 and ERK1/2 in pathologic scar tissue
下载PDF
导出
摘要 目的:检测病理性瘢痕组织中SDF-1,CXCR4及ERK1/2的表达并探讨其在病理性瘢痕中的相互作用机制。方法:采用免疫组织化学SABC法检测66例病理性瘢痕,25例非病理性瘢痕及27例正常皮肤中SDF-1,CXCR4及ERK1/2的表达。结果:与正常皮肤及非病理性瘢痕相比,SDF-1、CXCR4及ERK1/2三者在病理性瘢痕中均高表达(P<0.05);在病理性瘢痕中,SDF-1与ERK1/2的表达呈正相关关系(r=0.293,P<0.05),CXCR4和ERK1/2的表达呈正相关关系(r=0.284,P<0.05)结论:SDF-1/CXCR4生物轴在病理性瘢痕形成过程中可能通过调节ERK1/2途径从而在病理性瘢痕的增生中发挥重要作用。 Objective To explore the expressions of SDF-1, CXCR4 and ERK1/2 in pathologic scar. Methods The expressions of SDF-1, CXCR4 and ERK1/2 in 66 cases of pathologic scar, 25 cases of non-pathologic scar, and 27 cases of normal skin tissue were detected using immunohistochemical method. Results The positive expression of SDF-1, CXCR4 and ERK1/2 in normal skin and non-pathologic scar were significantly lower than in pathologic scar (P〈 O.05).The expression of ERK1/2 was significantly correlated with SDF-1 and CXCR4 in pathologic scar (P〈O.05). Conclusion The performance of the SDF-1/CXCR4 axis's biological function in pathologic scar may be correlated with the expression of ERK1/2.
出处 《中国美容医学》 CAS 2009年第11期1638-1639,共2页 Chinese Journal of Aesthetic Medicine
关键词 病理性瘢痕 SDF-1 CXCR4 ERK1/2 免疫组化 pathologic scar SDF-1 CXCR4 ERK1/2 immunohistochemistry
  • 相关文献

参考文献6

  • 1Pathl HL. Activator and target genes of Rel/ NF- B transcription factors[J]. Oncogene,1999,18:6853-6866.
  • 2Horuk R. Chemokines beyond inflammation[J]. Nature, 1998,393 (66 85) :524-525.
  • 3李娟,何涛.胞外信号调节激酶(ERK)信号转导途径的研究进展[J].四川生理科学杂志,2004,26(2):87-89. 被引量:15
  • 4Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth vascularization and metastasis[J]. FASEB J,2004,18(11): 1240-1242.
  • 5Tomohiko M,Ryuichiro D,Masayuki K,et al.CXCR4 antagonist inhibits stromal cell-derived factor induced migration and invasion of human pancreatic cancer[J]. Molecular Cancer Therapeutics,2004,3(1):29-37.
  • 6储子彦,陈晓萍,方晶晶.趋化因子SDF-1及受体CXCR4研究进展[J].生物学杂志,2006,23(1):11-13. 被引量:7

二级参考文献28

  • 1Lataillade J J, Clay D, Dupuy C, et al. Chemokine SDF - 1 enhances circulating CD34^+ cell proliferation in synergy with cytokines possible role in rogertitor survival[J]. Blood,2000,95:756 - 768.
  • 2Vaday GG, Hdey O. Extracellular matrix motictis, Cytokines, and enzymes, dynamic effects on immune cell behavior and inflammation [J] .J Leukoe Biol,2000,67:149 - 159.
  • 3Levesque JP, Hendy T, Takamatsu Y, et al. Disruption of the CXCR4/CXCLR chemotactic interaction during hematopoictic stem cell mobilization induced by G - SCF or cyclophosphamide [ J ]. J Clin Invest, 2003,111 : 187 - 196.
  • 4Wright DE, Bowtnan EP, Wagers AJ, et al. Hematopoictic stem cells are uniquely selective in their migratory response to chemokities[J]. J Exp Med,2002, 195:1145 - 1154.
  • 5Benboubker L, Watier H, Cation A, et al. Br J Haematol, 2001,113 (1):247.
  • 6Naiyer AL, Jod Y, Ahn J, et al. Stromal derived factor- 1 induced chemokines of cord blood CD34^+ cells (long term culture irtitiating cells) through endothelial cells is mediates by E- selectin [ J]. Blood, 1999,94.4011 - 4019.
  • 7Egawa T, Kawabata K, Kawamoto H, et al. The earliest stages of B cell development require a chemokine stromal cell- derived factor/pre - B cell growth - stimulating factor[J]. Immunity,2001,15(2) : 323 - 334.
  • 8[1]Gary L. Johnson, Razvan Lapadat. The protein kinase complement of the human genome. Science, 2002;296(6): 1911 ~1912.
  • 9[2]Walter Kolch. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. J.Biochem., 2000; 351: 289~ 305.
  • 10[3]Sun H., King A.J., Diaz, H.B., et al. Regulation of the protein kinase raf-1 by oncogenic ras through phosphatidylinositol 3- kinase, Cdc42/Rac and Pak. Curr. Bid.,2000; 10: 281~ 284.

共引文献20

同被引文献27

  • 1刘峥嵘,孙慧,张秋堂.CXCR4在急性B淋巴细胞白血病的表达及其意义[J].中国实验血液学杂志,2004,12(4):441-444. 被引量:5
  • 2张淑杰,刘明,王瑞芬,王正彩,王立峰.人脑星形胶质细胞瘤血管内皮生长因子表达、血管生成及细胞增殖活性的研究[J].哈尔滨医科大学学报,2007,41(3):230-233. 被引量:1
  • 3Fierro FA,Brenner S,Oelschlaegel U,et al.Combining SDF/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia[J].Leukemia,2009,23(2):393-396.
  • 4Sibley CR,Seow Y,Wood MJ.Novel RNA-based strategies for therapeutic gene silencing[J].Mol Ther,2010,18(3):466-476.
  • 5Di Cesare S,Marshall JC,Fernandes BF,et al.In vitro characterization and inhibition of the CXCR4/CXCL12 chemokine axis in human uveal melanoma cell lines[J].Cancer Cell Int,2007,14(7):17.
  • 6Lazennec G,Richmond A.Chemokines and chemokine receptors:new insights into cancer-related inflammation[J].Trends Mol Med,2010,16(3):133-144.
  • 7Wu X,Lee VC,Chevalier E,et al.Chemokine receptors as targets for cancer therapy[J].Curr Pharm Des,2009,15(7):742-757.
  • 8Gelmini S,Mangoni M,Serio M,et al.The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis[J].J Endocrinol Invest,2008,31(9):809-819.
  • 9Murakami T,Cardones AR,Hwang ST.Chemokine receptors and melanoma metastasis[J].J Dermatol Sci,2004,36(2):71-78.
  • 10Payne AS,Cornelius LA.The role of chemokines in melanoma tumor growth and metastasis[J].J Invest Dermatol,2002,118(6):915-922.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部